drugset
Drugs / Vi-TCV
last change Jan 2025 re-read 3 minutes ago

Vi-TCV

also known as Vi-Typhoid Conjugate Vaccine

Vaccine

Developed for
typhoid fever
Investigated by
Bill and Melinda Gates Foundation · Malawi-Liverpool-Wellcome Trust Clinical Research Programme · University College, London · University of Malawi · University of Maryland, Baltimore · University of Oxford

Trials 2

today NCT03299426 · Ph 3 NCT02324751 · Ph 2
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial · 1 met primary
Phase 2 NCT02324751 Sep 2015 → Dec 2017 typhoid fever University of Oxford Completed Met primary
Phase 31 trial · 1 met primary
Phase 3 NCT03299426 Feb 2018 → Jan 2025 overdue typhoid fever University of Maryland, Baltimore Active not recruiting Met primary

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Vi-TCV ClinicalTrials.gov intervention name — accepted as the source's own label NCT02324751 ↗
1

NCT03299426 ↗
Known as Vi-Typhoid Conjugate Vaccine “Vi-Typhoid Conjugate Vaccine (Vi-TCV)” NCT03299426 ↗
Modality Vaccine “Vi-tetanus toxoid conjugate vaccine” PMID 28965718 ↗ Sep 2017
Route Intramuscular “Single 0.5-ml intramuscular injection” NCT03299426 ↗